US EditionPfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows
Pfizer's profit guidance rises despite a 25% drop in Comirnaty vaccine sales due to narrowed federal recommendations and delayed updated shot approvals, officials said.
- This season, Pfizer's Comirnaty sales started slowly after federal regulators narrowed eligibility, with U.S. revenue falling to $870 million in the third quarter as delayed approval also hurt sales.
- Following changes at the CDC last month, federal guidance adopted recommendations from advisers picked by U.S. Health Secretary Robert F. Kennedy Jr., shifting booster advice and confusing drugstore customers.
- At Bay Street Pharmacy in Sebastian, Florida, Theresa Tolle said this fall has been confusing, with some customers declining shots and others fearful, while some locations required prescriptions.
- Public health experts warn vaccine rates have been suboptimal in recent years and could fall further this season, while Wall Street analysts expect Moderna's Spikevax sales to tumble about 50%.
- A major industry group and insurers clarified coverage as America's Health Insurance Plans said members will cover shots and CVS Health announced earlier this month it will not require prescriptions after sales rose first two quarters of the year and Moderna prepares third-quarter results Thursday.
61 Articles
61 Articles
Pfizer COVID shot sales plummet after Trump administration ends universal recommendations
U.S. sales of Pfizer's Comirnaty shots have taken a nosedive since the Trump administration updated its immunization schedules last month and dropped the universal collective recommendations for COVID-19 vaccines.The pharmaceutical company's revenues for the third quarter of 2025 are down 6% — amounting to a $1 billion drop — compared to the same stretch the previous year.'CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterre…
Pfizer COVID-19 Vaccine Sales Drop After CDC Narrows Guidance
Pfizer reported a decline in revenue on Nov. 4, which it primarily attributed to lower sales for the company’s COVID-19 vaccine, Comirnaty, and COVID-19 drug, Paxlovid. The company said it made $16.7 billion in revenue in the third quarter, down 7 percent from Q3 2024. “We saw solid contribution across our product portfolios … but it was more than offset by declines in Paxlovid and Comirnaty,” Pfizer Chief Financial Officer Dave Denton told inve…
Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows (Business)
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of updated shots also came several weeks later than usual, and Pfizer said Tuesday that hurt sales as ...
Santa Maria Times
Independent EspañolSales in the United States of Pfizer's Commonwealth vaccines fell 25% after federal regulators reduced recommendations on who should receive them, just as the COVID-19 vaccination season begins.
Pfizer Raises 2025 Profit Forecast for Second Time in a Row
Associated Press News
Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
